BEGIN:VCALENDAR

VERSION:2.0

PRODID:-//wp-events-plugin.com//7.2.2.1//EN

TZID:Asia/Jerusalem

X-WR-TIMEZONE:Asia/Jerusalem
BEGIN:VEVENT

UID:1196@biology.technion.ac.il

DTSTART;TZID=Asia/Jerusalem:20230904T133000

DTEND;TZID=Asia/Jerusalem:20230904T140000

DTSTAMP:20230829T084207Z

URL:https://biology.technion.ac.il/en/seminars/msc-graduate-seminar-stav-s
 hotan/

SUMMARY:Msc Graduate Seminar- Stav Shotan [No Categories]
DESCRIPTION:Location: Faculty Of Biology Auditorium/ZOOM: https://technion.
 zoom.us/j/99587628620   Stav Shotan\n Affiliation: \n Host:Associate Prof.
   David  Meiri \n A novel cannabinoid reduces uterine hyperplasia caused b
 y tamoxifen in mice\nUterine hyperplasia is characterized by overgrowth of
  cells in the lining of the uterus\, causing it to become thicker than usu
 al. Uterine hyperplasia can lead to irregular or heavy menstrual bleeding\
 , and in more severe cases\, it can increase the risk of developing endome
 trial cancer. The hormone estrogen plays a central role in endometrial pro
 liferation\, by binding to the estrogen receptor (ER) in the epithelial en
 dometrium. Many ER-positive breast cancer patients develop uterine hyperpl
 asia\, and it was found that some Selective Estrogen Receptor Modulators (
 SERMs) such as tamoxifen act as antagonists in the breast and as agonists 
 in the uterus. In the breast\, tamoxifen blocks estrogen from binding the 
 ER and hinders cell proliferation\, while in the uterus tamoxifen binds th
 e ER and coactivators complex and induces cell proliferation. In the Meiri
 ’s lab we have found a novel cannabinoid that reduces the expression of 
 the ER through the Hippo signaling pathway\, and enhances the effect of ta
 moxifen on breast cancer. Therefore\, we hypothesized this cannabinoid may
  reduce ER expression in the endometrium\, and thus attenuate tamoxifen-in
 duced uterine hyperplasia. We utilized a new model to study tamoxifen-indu
 ced hyperplasia\, and found the cannabinoid treatment decreased uterine ma
 ss\, luminal thickness and proliferation of epithelial cells\, resulting a
 lso in less tissue dysmorphology. To conclude\, this novel cannabinoid can
  relieve uterine hyperplasia manifestations\, and could be combined with t
 amoxifen for ER-positive breast cancer patients. By treating endometrial h
 yperplasia patients may avoid surgery and preserve fertility\, have increa
 sed long-term health and quality of life and adhere to SERMs treatment. 
LOCATION:Faculty Of Biology Auditorium/ZOOM: https://technion.zoom.us/j/995
 87628620

END:VEVENT

BEGIN:VTIMEZONE

TZID:Asia/Jerusalem

X-LIC-LOCATION:Asia/Jerusalem

BEGIN:DAYLIGHT

DTSTART:20230324T030000

TZOFFSETFROM:+0200

TZOFFSETTO:+0300

TZNAME:IDT

END:DAYLIGHT

END:VTIMEZONE
END:VCALENDAR